

Disclosures

Personal Commercial (14)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|------------------------------|--|--------------------------|---|
| <i>Self</i> | | | |
| Atropos Health | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Other</i> |
| Azurna | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Other</i> |
| Basking Bioscience | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Other</i> |
| Bitterroot | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Vascular Medicine</i> |
| BridgeBio | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Other</i> |
| Corsera Health | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Prevention</i> |
| Cytokinetics | Officer, Director, Trustee, or other Fiduciary Role | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Edwards Lifesciences | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Element Science | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Arrhythmias and Clinical EP General Cardiology</i> |
| HeartBeam | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Acute Coronary Syndromes</i> |
| Janssen Pharmaceuticals, Inc | Research/Research Grants ‡ <i>Trials in planning process (3 trials)</i> | Significant (>= \$5,000) | <i>Acute Coronary Syndromes Arrhythmias and Clinical EP Other</i> |
| Marea | Officer, Director, Trustee, or other Fiduciary Role | Significant (>= \$5,000) | <i>Prevention</i> |
| Merck & Co., Inc. | Data Safety Monitoring Board | Modest (< \$5,000) | <i>Prevention</i> |
| WebMD | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>General Cardiology Other</i> |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|---|--------------------|---------------|
| <i>Self</i> | | | |
| American Heart Association | Officer, Director, Trustee, or other Fiduciary Role | None (\$0) | <i>Other</i> |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (1)

| Funding Source | Institutional Compensation Level |
|------------------------|----------------------------------|
| Weill Cornell Medicine | Significant (>= \$5,000) |

Expert Witness Testimony (0)

No disclosures on record

‡ *Commercial Funding Source* | ‡ *Trial Name*

Agreement

Certified Education Attestation | Signed on 10/28/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/28/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/28/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/28/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.